Showing 2341-2350 of 5696 results for "".
- New MaximEyes.com Software Designed to Simplify EHR Navigation and Patient Flowhttps://modernod.com/news/new-maximeyescom-software-designed-to-simplify-ehr-navigation-and-patient-flow/2481076/First Insight has introduced MaximEyes.com, which is desinged go allow eye care processionals to access data—anywhere, anytime, from any device—in a web browser or via a local server.
- NIH Researchers Develop Gene Therapy for Rare Ciliopathyhttps://modernod.com/news/nih-researchers-develop-gene-therapy-for-rare-ciliopathy/2481074/Researchers from the National Eye Institute (NEI) have developed a gene therapy that rescues cilia defects in retinal cells affected by a type of Leber congenital amaurosis (LCA), a disease that causes blindness in early childhood. Using patient-derived retina organoids (also known as retinas-in-
- Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-submits-new-drug-application-to-the-fda-for-tp-03-for-the-treatment-of-demodex-blepharitis/2481073/Tarsus Pharmaceuticals announced that it has submitted a new drug application (NDA) to the FDA for TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of Demodex blepharitis. Demodex blepharitis is a highly prevalent eyelid m
- Glaukos Announces More Than 1 Million iStent Devices Implanted Worldwidehttps://modernod.com/news/glaukos-announces-more-than-1-million-istent-devices-implanted-worldwide/2481064/Glaukos announced that it has reached a milestone with its iStent family of technologies having now been implanted in more than 1 million procedures worldwide. “One million iStents implanted is a tremendous accomplishment and I’m grate
- Bausch + Lomb and Novaliq Announce FDA Filing Acceptance for Investigational Treatment NOV03 (Perfluorohexyloctane)https://modernod.com/news/bausch-lomb-and-novaliq-announce-fda-filing-acceptance-for-investigational-treatment-nov03-perfluorohexyloctane/2481063/Bausch + Lomb and Novaliq announced that the FDA has accepted the new drug application (NDA) filing for investigational treatment NOV03 (perfluorohexyloctane). A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs an
- eSight and Marathon Medical Partner to Provide Sight Medical Devices to the US Department of Veterans Affairshttps://modernod.com/news/esight-and-marathon-medical-partner-to-provide-sight-medical-devices-to-the-us-department-of-veterans-affairs/2481043/Vision-enhancement platform eSight and Marathon Medical Corp., a SDVOSB (Service-Disabled Veteran Owned Small Business) certified distributor to veteran medical facilities across the United States, announced that the’ve partnered to provide eSight 4 assistive eyewear medical devices to
- ESCRS Delegates Invited to Attend a ‘Cataract Surgery Virtual Reality (VR) Training Experience’https://modernod.com/news/escrs-delegates-invited-to-attend-a-cataract-surgery-virtual-reality-vr-training-experience/2481034/Haag-Stret is inviting ESCRS delegates to booth B86/B78 to attend a "Cataract Surgery Virtual Reality (VR) Training Experience," and witness some of the exciting features of the Haag-Streit Simulation
- High-Tech Imaging Reveals Details About Rare Eye Disorderhttps://modernod.com/news/high-tech-imaging-reveals-details-about-rare-eye-disorder/2481022/Using a new imaging technique, researchers from the National Eye Institute (NEI) have determined that retinal lesions from vitelliform macular dystrophy (VMD) vary by gene mutation. Addressing these differences may be key in designing effective treatments for this and other rare diseases, accordi
- Clearside Biomedical Enters Into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for Up to $65 Millionhttps://modernod.com/news/clearside-biomedical-enters-into-non-dilutive-financing-agreement-with-healthcare-royalty-partners-for-up-to-65-million/2481020/Clearside Biomedical announced it has entered into an agreement with HealthCare Royalty Partners in a deal worth up to $65 million. Clearside intends to use the proceeds from the agreement to support ongoing clinical development of its pipeline, including CLS-AX (axitini
- Nova Eye Medical Announces Global Data Registry to Support Role of Canaloplasty for Glaucomahttps://modernod.com/news/nova-eye-medical-announces-global-data-registry-to-support-role-of-canaloplasty-for-glaucoma/2481014/Nova Eye Medical announced the establishment of the iTrack Global Data Registry to collect prospective, multicenter, longitudinal data for canaloplasty in the treatment of glaucoma. A collaboration with the International Glaucoma Surgery Registry (IGSR), the iTrack Global